Skip to main content
. 2013 May 8;6:491–496. doi: 10.2147/OTT.S43287

Figure 2.

Figure 2

Kaplan–Meier estimates of PFS and OS in the clinical trial eligible group (arm eligible), according to treatment group. (A) PFS; the median was 4.2 months in GEM (gray line) and 5.9 months in GS (black line). (B) OS; the median was 9.6 months in GEM (gray line) and 10.7 months in GS (black line).

Abbreviations: PFS, progression-free survival; OS, overall survival; GEM, gemcitabine; GS, GEM + S-1 (tegafur, gimeracil, and oteracil potassium).